Actinium Pharmaceuticals, Inc. (ATNM)

NYSEAMERICAN: ATNM · IEX Real-Time Price · USD
5.10
-0.27 (-5.03%)
Jan 27, 2022 4:00 PM EST - Market closed
Market Cap112.36M
Revenue (ttm)1.12M
Net Income (ttm)-23.14M
Shares Out22.03M
EPS (ttm)-1.22
PE Ration/a
Forward PE6.84
Dividendn/a
Ex-Dividend Daten/a
Volume89,620
Open5.36
Previous Close5.37
Day's Range4.99 - 5.48
52-Week Range4.91 - 10.30
Beta0.53
AnalystsBuy
Price Target32.50 (+537.3%)
Earnings Daten/a

About ATNM

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a mu...

IndustryBiotechnology
Founded2000
CEOSandesh Seth
Employees32
Stock ExchangeNYSEAMERICAN
Ticker SymbolATNM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is 32.50, which is an increase of 537.25% from the latest price.

Price Target
$32.50
(537.25% upside)
Analyst Consensus: Buy

News

Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiothera...

NEW YORK and SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patie...

3 weeks ago - PRNewsWire

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A...

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unme...

1 month ago - PRNewsWire

Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 porti...

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unme...

1 month ago - PRNewsWire

Actinium Pharmaceuticals, Inc. Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Num...

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unme...

1 month ago - PRNewsWire

Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceutic...

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet...

1 month ago - PRNewsWire

Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy...

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unme...

2 months ago - PRNewsWire

Actinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation of Calreticulin Leading to Enh...

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unme...

2 months ago - PRNewsWire

Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refrac...

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet...

2 months ago - PRNewsWire

Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual...

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet...

2 months ago - PRNewsWire

Actinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapi...

NEW YORK, Oct. 1, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet...

3 months ago - PRNewsWire

Actinium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unm...

3 months ago - PRNewsWire

Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and N...

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unm...

4 months ago - PRNewsWire

Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief...

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unm...

4 months ago - PRNewsWire

Actinium to Present at Four Upcoming Investor Conferences

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unm...

4 months ago - PRNewsWire

Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERR...

4 months ago - PRNewsWire

Actinium Pharmaceuticals Announces Inclusion in Russell Microcap® Index

NEW YORK, June 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced today that it will be added to the Russell Microcap® Index at t...

6 months ago - PRNewsWire

Actinium Further Strengthens Patent Portfolio with International IP Covering the Composition and Methods of Administr...

NEW YORK, June 17, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its intellectual property portfolio around its lead Phase...

7 months ago - PRNewsWire

Actinium's Targeted Radiotherapy Achieves 100% Bone Marrow Transplant Engraftment

Actinium Pharmaceuticals Inc (NYSE: ATNM) highlighted data from its pivotal Phase 3 SIERRA trial evaluating Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (AML) aged 55 years and...

7 months ago - Benzinga

Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B pr...

NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted data from its pivotal Phase 3 SIERRA trial for Iomab-B in an...

7 months ago - PRNewsWire

Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receivi...

NEW YORK, June 15, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today highlighted safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patie...

7 months ago - PRNewsWire

Surging Earnings Estimates Signal Good News for Actinium (ATNM)

Actinium (ATNM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

7 months ago - Zacks Investment Research

Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells

Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of antibodies with the cell-ki...

7 months ago - Benzinga

Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Me...

NEW YORK, June 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and findings from the Co...

7 months ago - PRNewsWire

7 Reddit Penny Stocks Promising to Cure Cancer

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...

8 months ago - InvestorPlace

Actinium to Participate in the Cell & Gene Meeting on the Mediterranean

NEW YORK, March 31, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it will be participating in the Cell & Gene Meeting on t...

9 months ago - PRNewsWire